Zylt pills 75mg №84

Packaging

84 pcs.

Mechanism of action

Zylt - antiplatelet. Clopidogrel prevents the binding of adenosine phosphate (ADP) to the receptors located on the surface of platelets, and the activation of GP IIb / IIIa complex. This leads to inhibition of ADP-dependent platelet aggregation. It also leads to inhibition of platelet aggregation under the influence of other stimuli; the effect of ADP produced in each activated platelet is reduced, and the aggregation of the remaining platelets is stimulated. The effect of clopidogrel lasts throughout the life of the platelet, the platelet function is restored 7-10 days after discontinuation of clopidogrel.

Indications and usage

Prevention of ischemic disorders (myocardial infarction, stroke, thrombosis of peripheral arteries, sudden vascular death) in patients with atherosclerosis, including after myocardial infarction (up to 35 days), ischemic stroke (from 7 days to 6 months) or against the background of diagnosed occlusive peripheral arterial diseases.

Contraindications

• hypersensitivity to clopidogrel and / or any of the components of Zilt;
• severe liver failure;
• hemorrhagic syndrome, acute bleeding (including intracranial hemorrhage) and diseases predisposing to its development (peptic ulcer of the stomach and duodenum in the acute stage, ulcerative colitis, tuberculosis, lung tumors, hyperfibrinolysis);
• pregnancy;
• lactation period;
• age up to 18 years.

Dosage and administration

Zilt is taken orally, regardless of the meal. The recommended dose of Zilta for adults (including elderly patients) is 75 mg / day (table 1).

Special notes

In patients with myocardial infarction, Zylt treatment should not begin in the first few days after a heart attack. Clopidogrel prolongs bleeding time. Zilt should be administered with caution to patients with an increased risk of bleeding after injuries, operations or as a result of other pathological conditions, as well as patients with a tendency to bleeding (especially gastrointestinal and intraocular hemorrhages). Clopidogrel treatment should be discontinued at least 7 days before the planned surgical intervention (including dental procedures).

Drug interactions

The simultaneous administration of clopidogrel and Warfarin is not recommended due to the increased risk of bleeding. Acetylsalicylic acid does not alter the ADP-induced platelet aggregation caused by clopidogrel. However, the periodic appointment of acetylsalicylic acid (maximum 1 g for 24 hours) did not cause lengthening of the bleeding time. Clopidogrel can potentiate the effect of acetylsalicylic acid on platelet aggregation,induced by collagen. Therefore, the simultaneous administration of clopidogrel and acetylsalicylic acid is not recommended, since the risk of bleeding may increase. Due to the increased risk of bleeding, caution is advised when co-administered with clopidogrel and Heparin or other thrombolytic drugs. The simultaneous appointment of clopidogrel and NSAIDs increases the risk of erosive and ulcerative lesions of the gastrointestinal tract and ulcerative bleeding. Therefore, care should be taken when they are assigned at the same time. There was no clinical interaction with the simultaneous administration of clopidogrel and Atenolol, ACE inhibitors, blood cholesterol lowering agents, Nifedipine, Digoxin, phenobarbital, cimetidine, estrogen, theophylline. Clopidogrel inhibits the activity of the isoenzyme CYR2C9 with simultaneous use with drugs metabolized with the participation of this enzyme (phenytoin, tolbutamine), therefore it is possible to increase their concentrations in the blood plasma. Antacids do not affect clopidogrel absorption.

Overdosage

There is one message in the literature about deliberate overdose (intoxication). When taking 1050 mg of clopidogrel (14 tablets), no symptoms and signs of overdose were observed.

Storage conditions

The drug should be stored in a dry, dark place at temperatures not above 20 ° C.